Targets › IFNB1
2 programs from 2 companies in 3 trials: 2 Phase 3, 1 Phase 2; Immunology, Other, Infectious disease; next expected readout Jul 2030.
Type I interferon cytokine that plays a key role in the innate immune response to infection, developing tumors and other inflammatory stimuli. Signals via binding to high-affinity (IFNAR2) and low-affinity (IFNAR1) heterodimeric receptor, activating the canonical Jak-STAT signaling pathway resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon…. (UniProt, P01574)
Open in Phaseline: the race on IFNB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Dazukibart Interferon beta inhibitor | IFNB1 | Phase 3 | Myositis; Dermatomyositis | Jul 2030 |
| Centre Hospitalier Universitaire, Amiens | inhaled type I interferon type I interferon (IFN-β) with antiviral and immunomodulatory properties | IFNB1 | Phase 2 | COVID-19 | – |
Myositis (1) Dermatomyositis (1) COVID-19 (1)
antibody (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.